Plaza, VicenteAlobid, IsamAlvarez, CesáreoBlanco, MarinaFerreira, JorgeGarcía, GabrielGómez-Outes, AntonioGómez, FernandoHidalgo, AntonioKorta, JavierMolina, JesúsPellegrini, Francisco JavierPérez, MontserratPlaza, JavierPraena, ManuelQuirce, SantiagoSanz, José2023-05-032023-05-032021-05-26http://hdl.handle.net/10668/21988In this fifth phase of development, the contents of the Spanish Asthma Management Guidelines (GEMA), which include versions 5.0 and 5.1, have undergone a thorough review. The aim here is to set the main changes in context. These could be summarized as follows: DIAGNOSIS: new FENO cut-off and severity classification based on treatment needed to maintain control; INTERMITTENT ASTHMA: a more restrictive concept and treatment extended to include a glucocorticoid/adrenergic combination as needed; MILD ASTHMA: glucocorticoid/adrenergic therapy as needed as an alternative in case of low therapeutic adherence to conventional fixed-dose steroids; SEVERE ASTHMA: readjustment of phenotypes, incorporation of triple therapy in a single inhaler, and criteria for selection of a biologic in severe uncontrolled asthma; OTHERS: specific scoring in childhood asthma, incorporation of certain organizational aspects (care circuits, asthma units, telemedicine), new sections on COVID-19 and nasal polyposis.enAsmaAsthmaClinical practice guidelinesConsensoConsensusEvidence-based medicineGuía de práctica clínicaMedicina basada en la evidenciaresearch article3416785910.1016/j.arbres.2021.05.0101579-2129